Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression
Martina Sanlorenzo, Igor Vujic, Adil Daud, et al.
JAMA Dermatology (2015) Vol. 151, Iss. 11, pp. 1206-1206
Open Access | Times Cited: 423

Showing 1-25 of 423 citing articles:

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Jonathan J. Havel, Diego Chowell, Timothy A. Chan
Nature reviews. Cancer (2019) Vol. 19, Iss. 3, pp. 133-150
Open Access | Times Cited: 1954
Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance
Sreya Bagchi, Robert Yuan, Edgar G. Engleman
Annual Review of Pathology Mechanisms of Disease (2020) Vol. 16, Iss. 1, pp. 223-249
Open Access | Times Cited: 1558
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Satya Das, Douglas B. Johnson
Journal for ImmunoTherapy of Cancer (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 864
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer
Koji Haratani, Hidetoshi Hayashi, Yasutaka Chiba, et al.
JAMA Oncology (2017) Vol. 4, Iss. 3, pp. 374-374
Open Access | Times Cited: 862
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
John A. Thompson, Bryan J. Schneider, Julie R. Brahmer, et al.
Journal of the National Comprehensive Cancer Network (2019) Vol. 17, Iss. 3, pp. 255-289
Open Access | Times Cited: 515
Dermatologic Reactions to Immune Checkpoint Inhibitors
V. Sibaud
American Journal of Clinical Dermatology (2017) Vol. 19, Iss. 3, pp. 345-361
Closed Access | Times Cited: 501
Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints
Lee‐Shing Chang, Romualdo Barroso‐Sousa, Sara M. Tolaney, et al.
Endocrine Reviews (2018) Vol. 40, Iss. 1, pp. 17-65
Open Access | Times Cited: 435
Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy
Thomas Eigentler, Jessica C. Hassel, Carola Berking, et al.
Cancer Treatment Reviews (2016) Vol. 45, pp. 7-18
Closed Access | Times Cited: 380
Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor
Viswanath Reddy Belum, Benjamin Benhuri, Michael A. Postow, et al.
European Journal of Cancer (2016) Vol. 60, pp. 12-25
Open Access | Times Cited: 377
Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab
Koichi Sato, Hiroaki Akamatsu, Eriko Murakami, et al.
Lung Cancer (2017) Vol. 115, pp. 71-74
Open Access | Times Cited: 353
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable
Alessio Cortellini, Melissa Bersanelli, Sebastiano Buti, et al.
Journal for ImmunoTherapy of Cancer (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 338
Immune checkpoint inhibitor–related dermatologic adverse events
Amaris Geisler, Gregory S. Phillips, Dulce M. Barrios, et al.
Journal of the American Academy of Dermatology (2020) Vol. 83, Iss. 5, pp. 1255-1268
Open Access | Times Cited: 327
Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis
Biagio Ricciuti, Carlo Genova, Andrea De Giglio, et al.
Journal of Cancer Research and Clinical Oncology (2018) Vol. 145, Iss. 2, pp. 479-485
Closed Access | Times Cited: 307
PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
Junzo Hamanishi, Masaki Mandai, Noriomi Matsumura, et al.
International Journal of Clinical Oncology (2016) Vol. 21, Iss. 3, pp. 462-473
Open Access | Times Cited: 303
Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer
Karthik Suresh, Jarushka Naidoo, Cheng Ting Lin, et al.
CHEST Journal (2018) Vol. 154, Iss. 6, pp. 1416-1423
Open Access | Times Cited: 294
Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
Mario E. Lacouture, V. Sibaud
American Journal of Clinical Dermatology (2018) Vol. 19, Iss. S1, pp. 31-39
Open Access | Times Cited: 293
Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort
Shelley Ji Eun Hwang, Giuliana Carlos, Deepal Wakade, et al.
Journal of the American Academy of Dermatology (2016) Vol. 74, Iss. 3, pp. 455-461.e1
Open Access | Times Cited: 290
Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis
Xiaoxiang Zhou, Zhuoran Yao, Huaxia Yang, et al.
BMC Medicine (2020) Vol. 18, Iss. 1
Open Access | Times Cited: 266
Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies
V. Sibaud, Nicolás Meyer, Laurence Lamant, et al.
Current Opinion in Oncology (2016) Vol. 28, Iss. 4, pp. 254-263
Closed Access | Times Cited: 240
Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Immunotherapy
Veronica Shi, Nemanja Rodić, Scott Gettinger, et al.
JAMA Dermatology (2016) Vol. 152, Iss. 10, pp. 1128-1128
Open Access | Times Cited: 208
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial
Robert J. Motzer, Bernard Escudier, David F. McDermott, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 2, pp. e000891-e000891
Open Access | Times Cited: 204
Treatment Outcomes of Immune-Related Cutaneous Adverse Events
Gregory S. Phillips, Jennifer Wu, Matthew D. Hellmann, et al.
Journal of Clinical Oncology (2019) Vol. 37, Iss. 30, pp. 2746-2758
Open Access | Times Cited: 195
Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors
Alberto Pavan, Lorenzo Calvetti, Alessandro Dal Maso, et al.
The Oncologist (2019) Vol. 24, Iss. 8, pp. 1128-1136
Open Access | Times Cited: 192
Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy
Ying Jing, Jin Liu, Youqiong Ye, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 157
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients
Alessio Cortellini, Rita Chiari, Biagio Ricciuti, et al.
Clinical Lung Cancer (2019) Vol. 20, Iss. 4, pp. 237-247.e1
Closed Access | Times Cited: 148
Page 1 - Next Page

Scroll to top